" class="no-js "lang="en-US"> VistaPath - Medtech Alert
Wednesday, October 02, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
VistaPath | Pharmtech Focus

VistaPath

About VistaPath

VistaPath
VistaPath Biosystems is modernizing pathology labs using machine augmentation. Despite informing a majority of clinical decisions, anatomical pathology still prepares samples for diagnosis manually, in stark contrast to other clinical lab services. Driven by computer vision, we have developed a Workflow Management System which relieves highly paid technicians from manual tissue processing.

Related Story

Artificial Intelligence

 VistaPath Raises $4M to Modernize Pathology Labs Using Computer Vision and Artificial Intelligence | Pharmtech Focus

VistaPath Raises $4M to Modernize Pathology Labs Using Computer Vision and Artificial Intelligence

July 1 2022

VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced that […]